Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Guidelines
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
These guidelines include:
- General information about the Life Saving Drugs Program (LSDP)
- Treatment of hereditary tyrosinaemia (type 1) through the LSDP
- Drugs currently available for the treatment of hereditary tyrosinaemia (type 1) through the LSDP
- Choice of treatment
- General, initial and ongoing eligibility requirements
- LSDP funding conditions
- Exclusion criteria.